Close on Sep 18, 2026. Page updated Sep 19, 9:17 pm ET.
Elevance Health closes at $410.95, down 0.8%, holding above both its 50-day average of $397.21 and 200-day average of $363.09. The GekkoIndex reads 53.4, placing ELV in the Neutral zone, while the stock trades 33.5% below Gekko Fair Value of $618.14. Over the past year shares are up 33.2%, with a six-month return of 41.1%.
Recent coverage centers on valuation and margin questions alongside reaffirmed guidance. One piece compared ELV against American Well as an outperformer in the medical sector, while another weighed ELV against Danaher on value grounds. Elevance reaffirmed full-year 2026 earnings guidance of at least $20.10 per diluted share ($27.00 adjusted) and held its benefit expense ratio guidance at 90.2% plus or minus 50 basis points, with coverage noting net margin has thinned to 2.5% from a three-year average of 3.2%, tied to Medicaid segment underperformance even as Medicare Advantage has been restructured. BofA Securities raised its price target to $480 from $460 while maintaining a Buy rating. Separately, a 13F filing showed Corient Private Wealth LP cutting its ELV holding by 41.2% in the second quarter.
Elevance's next earnings report is set for 21 October, 31 days out and beyond a typical 20-trading-day hold. In the last 90 days there were 3 open-market insider purchases totaling $1,368,280. Seasonally, the next 20 trading days have averaged a 2.4% gain over 5 years, positive in 3 of those years. Analyst sentiment stands at 11 buy and 6 hold ratings among 17 firms, with a consensus target of $451.38.
Written by AI and checked automatically against the figures on this page. Generated Sep 20, 2026 from the data above.
Elevance Health scores 5 supportive, 1 mixed and 0 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
5 supportive1 mixed0 headwinds
Above 50 and 200-day
Close $410.95 is above the 50-day ($397.21) and 200-day ($363.09) averages, and the 50-day is above the 200-day.
See the chart53.4, Neutral
Reading 53.4 is in the Neutral zone.
See the GekkoIndex33.5% below
Price is 33.5% below Gekko Fair Value (more than 5% below).
See fair valueLeans bullish
Last 90 days: 3 open-market insider purchases.
See smart moneyReports in 31 days
Next report Oct 21, 2026, 31 days away — outside a typical 20-trading-day hold.
See earnings+2.4% on average
From this point in the calendar, the next 20 trading days averaged +2.4% over 5 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Elevance Health closed at $410.95 on Sep 18, 2026, +33.2% over the past year, inside a 52-week range of $274.84 to $436.24.
Use the left and right arrow keys to read daily values.
Put ELV on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Elevance Health works as a health benefits organization, helping people, families and communities navigate their health and wellness needs. It connects roughly 118 million individuals with care, support and resources aimed at helping them live healthier lives. Its reach spans medical coverage, digital health tools, pharmacy services, behavioral health support and clinical care solutions.
The company brings together a range of health-related services under one roof, addressing different aspects of a person's wellbeing rather than a single type of care. Its customer base is broad, serving individuals and families who rely on it for various forms of health assistance and coverage.
Elevance Health was founded in 1944 and is headquartered in Indianapolis, Indiana. It took on its current name in June 2022, having previously been known as Anthem, Inc. Its shares are listed on the NYSE under the ticker ELV.
Elevance Health’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 53.4, in the Neutral zone, up 2.9 points over five sessions.
Up 2.9 points over five sessions.
Reading for Sep 18, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 36 | −0.3% | −2.7% | ||
| Accumulation | 219 | −0.3% | −0.9% | ||
| Neutral (current zone) | 367 | +0.2% | +0.4% | ||
| Distribution | 38 | +0.5% | +1.2% | ||
| Selling | 2 | Too few readings yet | |||
Average ELV share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.2% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Elevance Health trades 33.5% below Gekko Fair Value of $618.14, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Elevance Health shares are worth, recalculated every trading day.
$618.14
Gekko Fair Value, Sep 19, 2026
33.5% Undervalued
Insiders filed 3 open-market purchases in Elevance Health worth $1.37M, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
$1.37Min 3 open-market purchases
| Filed | Insider | Type | Value |
|---|---|---|---|
| Jul 17 | Ramiro G Peru Director | Purchase | $366K |
| Jul 17 | Gail Boudreaux President and CEO | Purchase | $753K |
| Jul 17 | Gail Boudreaux President and CEO | Purchase | $249K |
From Form 4 filings, dated to when each was filed.
No trades in ELV were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Elevance Health has been buying back its own shares.
From company filings.
1of the funds Gekko tracks holds ELV.
Elevance Health reports on Oct 21, 2026, before the open (31 days away), and beat the EPS estimate in 5 of its last 8 reports.
Oct 21, 2026
Expected before the open, 31 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 15, 2026 | $7.45 est $6.18 | — est $48.82B | −12.6% |
| Apr 22, 2026 | $12.58 est $10.81 | $49.49B est $48.20B | +5.5% |
| Jan 28, 2026 | $3.33 est $3.10 | $49.31B est $49.84B | +7.5% |
| Oct 21, 2025 | $6.03 est $4.93 | $50.71B est $49.38B | −2.5% |
| Jul 17, 2025 | $8.84 est $8.91 | $49.78B est $48.19B | −19.6% |
| Apr 22, 2025 | $11.97 est $11.41 | $48.89B est $46.30B | +5.0% |
| Jan 23, 2025 | $3.84 est $3.85 | $45.44B est $44.95B | +2.6% |
| Oct 17, 2024 | $8.37 est $9.65 | $45.15B est $43.47B | −13.3% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Elevance Health is $451.38, +9.8% from the last close, from 17 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 17 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 18 | UBS | $460 | +11.9% |
| Sep 15 | Wells Fargo | $473 | +15.1% |
| Sep 11 | Barclays | $457 | +11.2% |
| Sep 11 | Bank of America Securities | $480 | +16.8% |
| Sep 9 | Bernstein | $488 | +18.7% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Sep 19, Elevance Health averaged +2.4% across the last 5 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −0.7% | 3 of 5 |
| Next 10 trading days | +0.1% | 1 of 5 |
| Next 15 trading days | +1.2% | 3 of 5 |
| Next 20 trading days | +2.4% | 3 of 5 |
| Next 30 trading days | +1.5% | 4 of 5 |
For scale, ELV’s typical 20-trading-day move in either direction is about 4.4%.
Elevance Health’s market cap is $89.12B, with a P/E ratio of 18.3 and revenue of $201.1B over the last twelve months.
Coverage of Elevance Health this week reads positive: 5 positive, 0 neutral and 1 negative headlines.
Elevance Health’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| UNHUnitedHealth | Accumulation | 0.2% below |
| CICigna | Accumulation | 37.8% below |
| HUMHumana | Accumulation | 24.5% below |
| CNCCentene | Neutral | 23.2% below |
| MOHMolina Healthcare | Neutral | 40.3% below |
| OSCROscar Health | Neutral | 0.5% below |
A peer links to its own page where one exists.
Elevance Health’s market cap is $89.12B at the Sep 18, 2026 close of $410.95, with 216.9M shares outstanding. The shares trade on a P/E ratio of 18.3.
The consensus analyst 12-month price target for Elevance Health is $451.38, +9.8% from the last close. Of the 17 firms that rated the stock in the last 90 days, 11 rate it a buy, 6 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Elevance Health is undervalued: the Sep 18, 2026 close of $410.95 is 33.5% below Gekko Fair Value of $618.14. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Elevance Health is expected to report on Oct 21, 2026, before the market opens (31 days away). Analysts expect earnings of $4.66 per share on revenue of $49.30B. Elevance Health beat the earnings estimate in 5 of its last 8 reports, moving 8.6% on average across the report.
Elevance Health’s 52-week high is $436.24 and its 52-week low is $274.84; it closed at $410.95 on Sep 18, 2026, +33.2% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 5 of the 6 items with data read as supportive (trend, fair value, smart money, earnings risk and seasonality), 1 as mixed (gekkoindex). The checklist is a description of current data, not a recommendation.
Prices and signals update after every US market close; the GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,349 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.